Literature DB >> 10597799

Effect of tuberculosis therapy on nevirapine trough plasma concentrations.

G L Dean, D J Back, A de Ruiter.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10597799     DOI： 10.1097/00002030-199912030-00029

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  6 in total

Review 1.  Drug interactions between antiretroviral drugs and comedicated agents.

Authors:  Monique M R de Maat; G Corine Ekhart; Alwin D R Huitema; Cornelis H W Koks; Jan W Mulder; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 2.  Clinically significant interactions with drugs used in the treatment of tuberculosis.

Authors:  W W Yew
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 3.  Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all.

Authors:  Awewura Kwara; Geetha Ramachandran; Soumya Swaminathan
Journal:  Expert Opin Drug Metab Toxicol       Date:  2010-01       Impact factor: 4.481

4.  Risk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIV-positive adults treated in rural northwestern Uganda.

Authors:  Laurence Ahoua; Gunar Guenther; Loretxu Pinoges; Paul Anguzu; Marie-Laure Chaix; Clotilde Le Tiec; Suna Balkan; David Olson; Charles Olaro; Mar Pujades-Rodríguez
Journal:  BMC Infect Dis       Date:  2009-06-03       Impact factor: 3.090

5.  Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients.

Authors:  Doaa Elsherbiny; Karen Cohen; Britt Jansson; Peter Smith; Helen McIlleron; Ulrika S H Simonsson
Journal:  Eur J Clin Pharmacol       Date:  2008-08-27       Impact factor: 3.064

6.  Durability of stavudine, lamivudine and nevirapine among advanced HIV-1 infected patients with/without prior co-administration of rifampicin: a 144-week prospective study.

Authors:  Weerawat Manosuthi; Preecha Tantanathip; Wisit Prasithisirikul; Sirirat Likanonsakul; Somnuek Sungkanuparph
Journal:  BMC Infect Dis       Date:  2008-10-14       Impact factor: 3.090
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.